Tod’Aérs Senior Partner Nersey Rastan Advances AI and Interoperability for More Accessible Clinical Trials

Mr. Nersey Rastan, Senior Partner and Executive Vice President for Global Advisory at Tod’Aérs Global Network [TGN], continues to contribute to major international discussions on artificial intelligence, healthcare data interoperability, and the future of clinical trials.

At the HL7 Connectathon 42 in Rotterdam, Mr. Rastan co-led the AI Eligibility Criteria Structuring Vulcan Track, using The Synergist.org’s and PFMD’s CTDN platform as a live test environment. The work delivered concrete results, with 141 eligibility criteria structured and expert-validated across six real clinical trials. Patient-matching logic, which can normally take specialists several days to generate, was produced in approximately three hours.

The initiative also demonstrated a successful end-to-end test matching FHIR-structured eligibility criteria against real patient records. This work highlighted the growing maturity of healthcare interoperability standards and the potential of AI-enabled infrastructure to make clinical trial data more accessible, structured, and actionable.

Following the Rotterdam work, Mr. Rastan participated in an invitation-only summit at the Royal Society of Medicine in London, co-hosted by IgniteData, Newmarket Strategy, and HL7 Vulcan. The event brought together leaders from the NHS, NIHR Research Delivery Network, Health Data Research UK, pharmaceutical companies, research institutions, and clinical research organizations from across the United Kingdom and Europe.

During a panel on interoperability and clinical trial competitiveness, Mr. Rastan shared insights on how standards such as FHIR, combined with AI and strong data curation layers, can support more efficient clinical research systems. The discussion emphasized that while the technology and infrastructure are increasingly ready, the next challenge is execution through real-world pilots and large-scale implementation.

His participation reflects his continued leadership in building AI infrastructure for more equitable clinical trials. It also aligns with TGN’s commitment to advancing innovation, digital transformation, health technology, and data-driven solutions with real-world impact.

Through his work across clinical research, interoperability, and AI-enabled healthcare systems, Nersey Rastan contributes to a future where clinical trials can become more efficient, inclusive, and accessible to the patients who need them most.